Neuron23
Changing the future of Parkinson's disease.
- Headquarters
- South San Francisco, California
- Employees
- 11–50
- Founded
- 2018
- Business Model
- B2B
- Website
- neuron23.com
- Total Funding
- $310.0M
- Last Round
- $96.5M Series DJun 2025
About
Neuron23 is a clinical-stage biotechnology company combining human genetics and data science to develop precision medicines for Parkinson's disease. Its lead program targets LRRK2, a genetic driver of Parkinson's, using machine learning and functional genomics to identify and match patients to therapies. The company was founded in 2018 by a team of drug hunters, geneticists, and neuroscientists.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account